![]() Elna, let’s talk a little more about taking this back to the clinics. We’ve learned about the effects on the ability of the red cell to circulate. ![]() Now Viewing EP: 4.RBC Health Clinical Assessment EP: 5.Clinician Awareness of RBC Health and Related Laboratory Measurements EP: 6.Patient Conversations Regarding RBC Health EP: 7.Role of Unhealthy RBCs in Blood Disorders EP: 8.Characteristics of an Unhealthy RBC EP: 9.Impact of Biochemical, Epigenetic, and Genetic Factors in RBC Health EP: 10.Impact of RBC Disorders on Patient QoL EP: 11.An Overview of Sickle Cell Disease (SCD) EP: 12.SCD: Unmet Needs, Prevalence, and Burden of Disease EP: 13.Exploring Patient-Reported Disease Burden and Unmet Needs EP: 14.Conversations Surrounding SCD Treatment Options EP: 15.Current FDA-Approved Therapies for SCD Management EP: 16.Exploring Emerging Therapies and Their Potential for Curative Intent in SCD EP: 17.Role of Gene Therapy in SCD Management EP: 18.Role of Clinical Trial Endpoints and Metrics in SCD Therapies EP: 19.Increasing Confidence in Emerging Therapies EP: 20.Utility of Potential SCD Biomarkers in SCD Management EP: 21.Practice Pearls for the Management of SCDīiree Andemariam, MD: We’ve learned about the biochemistry. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |